Navigation Links
ALS Therapy Development Institute Delivers Impassioned Testimony to Congressional Subcommittee on Veterans Affairs
Date:4/28/2009

Physician/Scientist Describes a New Challenge Faced by Troops Coming Home from War

CAMBRIDGE, Mass., April 28 /PRNewswire-USNewswire/ -- Dr. Stanley Appel testified before theMilitary Construction and Veterans Affairs Appropriations Subcommittee on behalf of ALS patients, and in support of the ALS Therapy Development Institute (ALS TDI), last Thursday. Dr. Appel urged congress to support a comprehensive approach to ALS therapeutic development, such as the one at ALS TDI.

Dr. Appel spoke on the still unknown reasons for the connection between service in the armed forces and a greater propensity for developing the disease. He advised Subcommittee members to remember that, while there is excellent work being done to determine factors involved in the military correlation, without a comprehensive and well funded program to build therapeutics, there would be no opportunity to treat fallen heroes.

"I am here before this subcommittee -- responsible for supporting our veterans -- because [ALS] continues to take an inordinate toll on our nation's veterans," said Dr. Appel in his prepared testimony before the subcommittee. Dr. Appel, co-director of the Methodist Neurological Institute, has been a physician/scientist for more than 40 years and is a Board Member of ALS TDI, as well as the Muscular Dystrophy Association.

As he began his testimony, Dr. Appel acknowledged the leadership of Congressman Michael Capuano, along with Congressmen Patrick Kennedy, Henry Brown and John Spratt in addressing the need to bring effective therapeutics to market for ALS patients.

In discussing the VA's now closed ALS Registry, Dr. Appel honored its list of servicemen; "While most of those heroes have passed away, the numbers imply that at least one out of fifteen ALS patients has a history of military service. This is quite staggering. These veterans, and all the patients I treat, are facing a horrifying illness; a battle with no armor," continued Dr. Appel. "We have the responsibility to arm our service members in the final battle they are currently only to lose. The thousands, who have recently returned from engagement, and those soon to come home, may in fact encounter a final new enemy in ALS."

Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive neurodegenerative disease that affects approximately 30,000 people living in the United States at any given time. According to Dr. Appel's testimony, more than 2,000 veterans registered as suffering from ALS when the Department of Veterans Affairs initiated its voluntary ALS Registry in 2003.

The subcommittee, chaired by Congressman Chet Edwards, known as a national champion for America's veterans, troops, and their families, is responsible for the appropriation of funds for a variety of military related accounts, including all funds administered by the Department of Veterans Affairs. Under Edwards' leadership, the subcommittee has increased appropriations for veteran's benefits and health care by $16.3 billion since 2007.

"ALS is not an incurable disease. It is an underfunded disease. The science is ready, the technology is ready, we clinicians are ready." Dr. Stanley Appel's complete testimony before the subcommittee is available online at www.als.net.

About ALS TDI

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that stop ALS as soon as possible. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, as well as a multi-pronged approach to validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs. The Institute's unique, industrial-scale platform allows for the development and testing of dozens of potential therapeutics each year. Built by and for patients, the Institute is the world's only non-profit biotechnology company with more than 30 professional scientists. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry. For more information, please visit us online at www.als.net.


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prostate cancer therapy increases risk of fractures and cardiovascular-related death
2. MedicareSupplementPlans.com Says News Legislation Could Affect Physical, Speech Therapy Benefits for Medicare Recipients
3. Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
4. CIDP Treated With Plasma-Derived Therapy
5. G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab
6. Elekta Contract Provides MAGNET Cooperative Access to Leading Radiation Therapy Solutions
7. Hormone therapy offers potential protective effect against colon cancer in older women
8. RapidArc Radiotherapy Technology Enabling Fast, Accurate Treatments for Pennsylvania Cancer Patients
9. Illinois-Based AthletiCo Opens Milestone 50th Physical Therapy Center
10. Medical Tourism is Good Therapy for the Hotel Industry
11. Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Hamlin ... to announce that they are sponsoring a raffle. Throughout the month of February, patients ... will receive a gift card for a dinner for two at the Cheesecake Factory. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... for the National Institute for Health and Care Excellence (NICE) framework. ... the National Health Service (NHS) to search, order and purchase medical and healthcare-related ...
(Date:2/23/2017)... ... 23, 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive dental ... named a 2017 Top Patient Rated Henderson Dentist by Find Local Doctors ... local physicians and dentists who have earned high ratings and superior patient reviews from ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... CITY, Calif., Feb. 23, 2017 Nevro Corp. (NYSE: ... evidence-based solutions for the treatment of chronic pain, today reported ... December 31, 2016. 2016 Accomplishment & Highlights: ... full year 2016, an increase of 228% as reported, over ... for 2016, an increase of 612% over the prior year ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Fibromyalgia ...
(Date:2/23/2017)... , February 23, 2017 ... Market by Product (X-ray Imaging Digital, Analog), MRI (Closed, ... (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) ... report studies the global market over the forecast period ... reach ~USD 36.43 Billion by 2021, at a CAGR ...
Breaking Medicine Technology: